Related Experiment Video

Updated: Jun 27, 2026

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation
10:15

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Published on: March 22, 2017

Follow-up of children who received complex invasive therapies early in life

Reg Sauve1, Charlene Mt Robertson

  • 1Departments of Pediatrics and Community Health Sciences, University of Calgary, and Alberta Children's Hospital, Calgary.

Paediatrics & Child Health
|November 26, 2008
PubMed

Insights

This review examines outcomes for children receiving complex pediatric therapies in Alberta. While serious conditions are rare, developmental delays are common, aiding parent counseling and outcome improvement efforts.

Area of Science:

  • Pediatric Medicine
  • Rehabilitation Therapy
  • Clinical Outcomes Research

Background:

  • Complex pediatric therapies are crucial for infants and children with serious health conditions.
  • Standardized outcome assessment is essential for evaluating the effectiveness of these therapies.
  • Existing literature and registry data provide insights into patient trajectories.

Purpose of the Study:

  • To review existing literature on outcome assessment in complex pediatric therapy programs.
  • To discuss enrollment and assessment processes within the Complex Pediatric Therapies Registry in Alberta.
  • To analyze outcomes and predictors of adverse events in infants and children receiving complex therapies.

Main Methods:

  • Systematic review of published literature on pediatric therapy outcomes.
  • Analysis of data from the Complex Pediatric Therapies Registry in Alberta.
  • Longitudinal follow-up of 483 infants and children surviving to discharge.

Main Results:

  • High compliance rates (≥96%) observed at baseline, 18 months, and 4 years.
  • Cerebral palsy, blindness, and deafness were rare among the study population.
  • Developmental delay and borderline cognitive function were more frequently observed outcomes.

Conclusions:

  • Complex pediatric therapies can lead to positive outcomes with rare severe impairments.
  • Identification of predictors for adverse outcomes allows for improved parent counseling.
  • Ongoing assessment and data collection are vital for refining therapeutic interventions and improving child development.

Keywords:
Follow-upLife-saving paediatric therapiesOutcomes

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...